Forsteo for glucocorticoid-induced osteoporosis

The licence for Forsteo (teriparatide) has been extended to include the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

The recommended dose of Forsteo is 20 micrograms administrated once daily by subcutaneous injection in the thigh or abdomen. The maximum total duration of treatment should be 18 months. The 18-month course should not be repeated over a patient’s lifetime.

View Forsteo drug record

Further information: Lilly

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more